When does CroFab lose exclusivity?
CroFab (Crotalidae Polyvalent Immune Fab) is an FDA-approved antivenom product. However, the exact date of “loss of exclusivity” depends on which exclusivity protection you mean (for example, specific marketing exclusivity tied to an approval pathway, patent expirations, or any exclusivity extensions). The provided information does not include CroFab’s Orange Book entries, patent numbers, or FDA exclusivity periods, so a specific loss-of-exclusivity date can’t be determined here.
What does “loss of exclusivity” usually mean for a drug like CroFab?
For an FDA-approved drug, “loss of exclusivity” typically refers to a point when the manufacturer’s protected period ends, allowing generic or biosimilar-like competition (depending on the product category and regulatory pathway). In practice, entry timing can also be influenced by:
- Patent expirations (and any “listed patents” in the FDA Orange Book)
- Remaining regulatory exclusivities (if any)
- Litigation and stays, if a challenge is filed
- Whether a product is eligible for an abbreviated pathway or requires a more complex development program
Can a competitor launch immediately after exclusivity ends?
Not necessarily. Even if exclusivity ends on a calendar date, a competitor’s launch may still be delayed by:
- Remaining unexpired patents
- Court-ordered injunctions or settlement terms
- Regulatory requirements to obtain approval for a competing product
Are antivenoms like CroFab subject to generic substitution?
Antivenoms often face more complicated substitution and competition dynamics than typical small-molecule drugs because of how they are produced and regulated. “Generic” terminology may not capture the true regulatory pathway for antivenom competitors, depending on product classification and approval history.
Where to find the real CroFab exclusivity/patent timeline
To pinpoint the true “loss of exclusivity” date, the most reliable sources are:
- FDA Orange Book for listed patents and exclusivity codes/expiration dates
- FDA approval history for the relevant approval and exclusivity grants
- Court dockets or FDA-related litigation if competitors have been blocked by patents
If you share the jurisdiction you care about (U.S. vs another country) and whether you mean “patent expiry” or “FDA exclusivity,” I can help narrow what to look for and how to interpret the Orange Book entries.
What I need from you to give a specific date
Please provide one of the following:
- The U.S. Orange Book listing (or screenshot/text) for CroFab, or at least the Orange Book patent “expiration dates” and exclusivity “type/expiration date.”
- The exact statement you saw about “loss of exclusivity” (sometimes it’s tied to a specific year or exclusivity code).
With that, I can translate it into a clear timeline for when competitors could realistically enter.